MALAT1 and prostate carcinoma: Almost 2-fold higher γH2AX foci per cell were noted in olaparib-treated MALAT1-silenced cells compared with shSCRM control (Fig. 6G and H), suggesting that MALAT1 deficiency exacerbates olaparib-induced DNA damage in prostate cancer cells.